BUZZ-MBX Biosciences reports one-year data for hormone disorder drug, shares fall

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00

** Shares of drug developer MBX Biosciences MBX.O fall 8.7% to $34 premarket

** MBX says its experimental once-weekly drug, canvuparatide, showed sustained benefit in patients with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

** In a one-year open-label extension study, 57% of patients met the main response criteria, compared with 63% response rate seen at 12 weeks in a mid-stage trial

** Investors were hoping to see a continuation of the 79% response rate seen at six months data, Barclays says

** Injection site reactions were reported in 10% of patients in the open-label extension study - MBX

** Company says it remains on track to start a late-stage trial in Q3 2026

** Up to last close, shares up 18% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.